New pill HPG1860 shows promise for fatty liver disease in early trial
NCT ID NCT05338034
First seen May 29, 2026 · Last updated Jun 23, 2026 · Updated 4 times
Summary
This Phase 2a trial tested three different doses of an oral drug called HPG1860 against a placebo in 89 adults with NASH, a serious fatty liver disease. The main goals were to check safety and see if the drug could reduce liver fat over 12 weeks. Results are complete, but the study is small and early, so more research is needed to know if HPG1860 truly helps control NASH long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASH - NONALCOHOLIC STEATOHEPATITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
South Texas Research Institute (STRI)
Texas City, Texas, 78240, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HPG1860 (an oral drug capsule)
What this could lead to
If successful, HPG1860 could offer a new oral treatment to reduce liver fat and control NASH, potentially slowing or stopping liver damage.
What could go wrong
This is an early Phase 2a trial with only 89 people. It primarily checks safety and short-term liver fat changes, not long-term outcomes. The drug may not prove effective in larger studies.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.